Versor Investments LP Acquires Shares of 7,100 AtriCure, Inc. (NASDAQ:ATRC)

Versor Investments LP bought a new position in AtriCure, Inc. (NASDAQ:ATRC) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 7,100 shares of the medical device company’s stock, valued at approximately $217,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ATRC. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in AtriCure by 31.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,649 shares of the medical device company’s stock worth $14,038,000 after purchasing an additional 119,929 shares during the last quarter. Champlain Investment Partners LLC boosted its holdings in AtriCure by 4.3% during the third quarter. Champlain Investment Partners LLC now owns 2,790,758 shares of the medical device company’s stock worth $78,253,000 after purchasing an additional 115,813 shares during the last quarter. Two Sigma Advisers LP boosted its holdings in AtriCure by 14.6% during the third quarter. Two Sigma Advisers LP now owns 664,100 shares of the medical device company’s stock worth $18,621,000 after purchasing an additional 84,700 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in AtriCure during the third quarter worth about $1,991,000. Finally, State Street Corp boosted its holdings in AtriCure by 4.9% during the third quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after purchasing an additional 63,002 shares during the last quarter. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure Stock Performance

NASDAQ ATRC opened at $38.16 on Wednesday. The company’s 50 day moving average is $37.52 and its 200-day moving average is $32.95. AtriCure, Inc. has a 12-month low of $18.94 and a 12-month high of $43.11. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.87 billion, a P/E ratio of -40.17 and a beta of 1.46.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. JPMorgan Chase & Co. boosted their price target on shares of AtriCure from $40.00 to $51.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. JMP Securities reiterated a “market outperform” rating and issued a $60.00 target price on shares of AtriCure in a research note on Monday, February 10th. Stifel Nicolaus boosted their target price on shares of AtriCure from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. Finally, Canaccord Genuity Group boosted their target price on shares of AtriCure from $61.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.56.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.